Moderna, Inc. Taxes Payable, Current
Moderna, Inc. (MRNA) had Taxes Payable, Current of $3.00 million as of 2024-12-31, per its 10-K filed 2025-02-21.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:TaxesPayableCurrent · last filed 2025-02-21
- 2024-12-31: Taxes Payable, Current $3.00M.
- 2024-09-30: Taxes Payable, Current $4.00M.
- 2024-06-30: Taxes Payable, Current $7.00M.
- 2024-03-31: Taxes Payable, Current $52.00M.
| Period end | Taxes Payable, Current |
|---|---|
| 2024-12-31 | $3.00M 10-K · filed 2025-02-21 |
| 2024-09-30 | $4.00M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $7.00M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $52.00M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $63.00M 10-K · filed 2025-02-21 |
| 2023-09-30 | $56.00M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $47.00M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $66.00M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $48.00M 10-K · filed 2024-02-23 |
| 2022-09-30 | $66.00M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $349.00M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $1.59B 10-Q · filed 2022-05-04 |
| 2021-12-31 | $876.00M 10-K · filed 2023-02-24 |
| 2021-09-30 | $565.00M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $377.00M 10-Q · filed 2021-08-05 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |